Clinical data | |
---|---|
Other names | MIJ821 |
Drug class | NMDA receptor modulator |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H23FN2O3 |
Molar mass | 358.413 g·mol−1 |
3D model (JSmol) | |
| |
|
Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.[1][2]